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IL-32 is a pro-inflammatory cytokine expressed by activated natural killer cells, T cells, keratinocytes, and
fibroblasts. In this study, we examined the role of IL-32 in cutaneous T-cell lymphoma (CTCL), including mycosis
fungoides (MF) and Se´zary syndrome (SS). IL-32 mRNA expression levels in lesional skin of MF patch, plaque, and
tumor were increased compared with those of normal skin, which positively correlated with CCL17 and CCL18
mRNA expression levels. Serum IL-32 levels positively correlated with disease activity within each patient.
Immunostaining showed that keratinocytes expressed IL-32 in the lesional skin of MF patch and plaque, whereas
in MF tumor, atypical T cells in the dermis strongly expressed IL-32. We also showed that IL-32 dose-dependently
accelerated the proliferation of MF and SS cell lines in vitro, which was inhibited by blocking mitogen-activated
protein kinase and NF-kB-mediated signaling. The addition of anti-IL-32 antibodies in culture decreased the
proliferation of SS cells and the viability of MF cells, suggesting that IL-32 serves as an autocrine growth factor. In
conclusion, our results suggest that IL-32 has a role in the formation and maintenance of CTCL lesions, providing
a possible therapeutic target for patients with this disease.
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INTRODUCTION
IL-32 was originally described as natural killer (NK) cell
transcript 4 found in activated NK cells and T cells and later
named IL-32 (Dahl et al., 1992). IL-32 is a pro-inflammatory
cytokine, which has a physiological role in T-cell commu-
nication. IL-32 is not only induced by various infectious
agents, such as mycobacterium, human immunodeficiency
virus, and influenza virus (Netea et al., 2006; Rasool et al.,
2008; Li et al., 2010), but is also involved in the inflammatory
processes of rheumatoid arthritis, chronic obstructive pulmo-
nary disease, and Crohn’s disease (Joosten et al., 2006; Shioya
et al., 2007; Calabrese et al., 2008). IL-32 is expressed by
keratinocytes and fibroblasts and by activated NK cells and T
cells (Dahl et al., 1992; Meyer et al., 2010). Recently, IL-32
was reported to be expressed in lesional skin of atopic
dermatitis, positively correlating with disease activity (Meyer
et al., 2010).
Mycosis fungoides (MF) and Se´zary syndrome (SS) are the
most common types of cutaneous T-cell lymphoma (CTCL).
Patients with MF typically have a prolonged clinical course
and only limited cases progress over the years through patch,
plaque, and tumor, followed by lymph node and visceral
involvement (Girardi et al., 2004). Most cases of MF/SS,
especially at an advanced stage, show a T-helper (Th)
2–dominant cytokine environment, characterized by increased
IL-4, IL-5, IL-10, and IL-13 production (Vowels et al., 1994;
Asadullah et al., 1996a). Quite recently, it was revealed that
IL-32 was expressed in MF tumor and in the MF cell line
MyLa, but not in early MF, benign controls, and normal skin
(van Kester et al., 2012). The aim of this study was to further
examine the role of IL-32 in patients with MF and SS. Our
findings suggest that IL-32 has an important role as an
autocrine and paracrine growth factor in CTCL, providing a
possible target for the treatment of CTCL.
RESULTS
IL-32 mRNA is expressed in lesional skin of CTCL, especially in
MF tumor
We examined IL-32 mRNA expression in lesional skin of MF/
SS and in normal skin by quantitative reverse transcription
(RT)-PCR. IL-32 mRNA expression in lesional skin of MF
patch, plaque, and tumor was increased compared with
normal skin (Figure 1a; Po0.05, respectively), whereas in
lesional skin of erythrodermic MF/SS, IL-32 levels were not
elevated. We also measured IL-32 mRNA expression in
lesional skin and non-lesional skin from the same patient in
11 MF cases (Figure 1b). In 9 of the 11 cases, IL-32 mRNA
expression in lesional skin was increased compared with non-
lesional skin (Figure 1b; Po0.05). We also found that IL-32
mRNA expression levels positively correlated with CCL17 and
CCL18 mRNA expression levels in lesional skin (Figure 1c and
d). Thus, IL-32 mRNA was expressed in MF lesional skin,
which reflected disease activity.
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Serum IL-32 levels positively correlate with disease activity
within individual CTCL patients
Serum IL-32 levels of patients with patch, plaque, tumor,
erythrodermic MF/SS, and healthy controls were 11.4±4.2,
10.3±3.2, 11.2±2.4, 12.2±3.9, and 15.6±3.1 pg ml–1,
respectively (Figure 2a). There were no significant differences
between the groups. Serum IL-32 levels in patients with SS
were 13.3±3.8 pg ml–1, which tended to be higher than the
levels in erythrodermic MF patients (9.1±1.9 pg ml–1), but this
did not reach statistical significance. We also measured serum
IL-32 levels in five MF/SS cases (three cases of tumor MF and
two cases of SS) before and after treatment, which included
topical and oral corticosteroids, UV phototherapy, oral etre-
tinate, and/or systemic chemotherapy (Figure 2b). In four of
the five cases, serum IL-32 levels after treatment were lower
than those before treatment (Figure 2b; Po0.05). Thus, serum
IL-32 levels may not be a disease-specific marker for differ-
entiating MF/SS from healthy controls, but may be positively
correlated with disease activity within each patient with CTCL.
Enhanced IL-32 protein expression in lesional skin of MF patch,
plaque, and tumor
Immunostaining revealed that IL-32 expression in lesional skin
of MF patch, plaque, and tumor was enhanced compared with
the expression in healthy controls (Figure 3). Keratinocytes
strongly expressed IL-32 in lesional skin of MF patch and
plaque, although in MF tumor IL-32 expression in keratino-
cytes was decreased. Interestingly, dermal-infiltrating CD4þ
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Figure 1. IL-32 mRNA expression in mycosis fungoides (MF) and Se´zary syndrome (SS). (a) IL-32 mRNA expression in lesional skin of patch, plaque, tumor MF,
and erythrodermic MF/SS. (b) IL-32 mRNA expression in lesional and non-lesional skin from MF patients. (c) Correlation between IL-32 and CCL17 mRNA
expression levels in lesional skin. (d) Correlation between IL-32 and CCL18 mRNA expression levels in lesional skin. *Po0.05 and **Po0.01. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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atypical T cells expressed IL-32 in this latter patient group
(Figure 3). In lesional skin of erythrodermic MF/SS, neither
keratinocytes nor dermal tumor cells expressed IL-32 (Figure 3),
which was consistent with the results of IL-32 mRNA expres-
sion (Figure 1a). Lesional skin with high IL-32 mRNA expres-
sion levels tended to show enhanced IL-32 expression by
immunohistochemical analysis. There was no significant
correlation between IL-32 mRNA expression levels in lesional
skin and serum IL-32 levels. We have summarized the results
of ELISA, quantitative RT-PCR, and immunohistochemical
analyses of IL-32 in CTCL patients in Table 1.
IL-32 accelerates the proliferation of CTCL cell lines through
mitogen-activated protein kinase (MAPK) and NF-jB signaling
pathways
In order to determine the effect of IL-32 on CTCL tumor cells,
we stimulated MyLa (MF cell line) and SeAx cells (SS cell line)
with IL-32 in vitro. IL-32 significantly accelerated MyLa
and SeAx cell proliferation in a dose-dependent manner
(Figure 4a). There were no differences in cell viability between
the IL-32-treated cells and control cells (data not shown). We
next explored signaling pathways involved in this proliferative
effect by adding U0126, a MAPK extracellular signal–reduced
kinase 1/2 inhibitor, sc-514, an IkB kinase-2 inhibitor, and
LY294002, a phosphatidylinositol 3-kinase inhibitor. On add-
ing U0126, cell proliferation of SeAx was decreased dose-
dependently in both untreated and IL-32-treated cells
(Figure 4b). When treated with 20mM of U0126, there were
no significant differences in cell numbers between the
untreated and IL-32-treated cells (Figure 4b and c). Similar
results were obtained when sc-514 was added, although
LY294002, which decreased cell numbers both in untreated
and in IL-32-treated groups, did not block cellular proliferation
induced by IL-32 (Figure 4b and c). These results suggest
that MAPK, NF-kB, and phosphatidylinositol 3-kinase/Akt
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Figure 2. Serum IL-32 levels in mycosis fungoides (MF) and Se´zary syndrome (SS). (a) Serum IL-32 levels in patients with MF and SS. (b) Serum IL-32 levels in MF/
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Figure 3. Immunohistochemical staining for IL-32. Representative pictures
of five cases in each group (scale bar¼ 100mm). Keratinocytes expressed
IL-32 in lesional skin of patch and plaque mycosis fungoides (MF), although
in tumor MF, dermal-infiltrating CD4þ atypical T cells strongly expressed
IL-32. H&E, hematoxylin and eosin; SS, Se´zary syndrome.
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signaling pathways are all associated with cell proliferation of
SeAx, whereas IL-32’s ability to accelerate cell proliferation is
mainly mediated by MAPK and NF-kB pathways.
Neutralization of IL-32 decreases proliferation of SS cells and
viability of MF cells
As the tumor cells in lesional skin of tumor MF expressed IL-32
(Figure 3), we next examined whether IL-32 could serve as an
autocrine growth factor. We first showed that the MF cell line
MyLa and the SS cell line SeAx expressed IL-32 mRNA by
real-time RT-PCR (Figure 5a). IL-32 protein was also detected
both in MyLa and in SeAx cell culture supernatants
(Figure 5b). When anti-IL-32 neutralizing antibody was added
to MyLa cells, there was no significant difference in the cell
number between the untreated and antibody-treated groups
(Figure 5c). On the other hand, cell numbers of antibody-
treated SeAx were significantly smaller than the cell numbers
of untreated SeAx (Figure 5c). When we analyzed cell
viability, IL-32 neutralization significantly decreased the sur-
vival rate in MyLa, whereas viability of SeAx was not changed
(Figure 5d). Thus, we found that IL-32 produced by CTCL cell
lines serves as an autocrine growth factor.
DISCUSSION
Our study revealed that IL-32 expression was increased in
lesional skin of MF, which was consistent with a recent report
(van Kester et al., 2012). Keratinocytes in lesional skin of early
MF (patch and plaque) expressed IL-32, whereas in MF tumor
IL-32 expression occurred in atypical T cells located in the
dermis and less so in the epidermis (Figure 3). IL-32 was
not expressed in the epidermis in erythrodermic MF/SS.
We also showed that IL-32 dose-dependently accelerated
the proliferation of MF and SS cell lines in vitro, which was
inhibited by blocking MAPK and NF-kB NF pathways. Finally,
we showed that IL-32 serves as an autocrine growth factor in
these cell lines.
IL-32 is highly expressed in human keratinocytes after
stimulation with Th1 cytokines, including IFN-g and tumor
necrosis factor-a (Meyer et al., 2010). IL-32 is highly expressed
in synovial tissue biopsies of rheumatoid arthritis cases and
IL-32 mRNA expression is increased in lesional skin of
psoriasis (Joosten et al., 2006; Kempuraj et al., 2010). IL-32,
however, was reported to be involved not only in these Th1-
type diseases but also in CTCL and atopic dermatitis (Meyer
et al., 2010; van Kester et al., 2012). Indeed, previous studies
have suggested that both Th2 cells and Th1 cells are present
within lesional skin of these latter two diseases (Grewe et al.,
1994; Asadullah et al., 1996b). In lesional skin of tumor MF
and SS, however, Th2 cells are dominant (Miyagaki et al.,
2010), which may explain why we saw low or no IL-32
expression in the epidermis in advanced CTCL.
Decreased IL-32 expression could lead to disease progres-
sion in CTCL. IL-32 enhanced the cytotoxic effect of NK cells
on colon and prostate cancer cells (Park et al., 2012).
Intratumoral injections of dendritic cells engineered to
express human IL-32b resulted in CD8þ T-cell–dependent
suppression of tumor growth in mice (Qu et al., 2011). Thus,
low or no IL-32 expression in the epidermis in advanced CTCL
may help tumor cells escape from immunosurveillance.
Dermal-infiltrating CD4þ atypical T cells strongly expressed
IL-32 in tumor MF, suggesting that tumor cells in advanced MF
acquired resistance to IL-32-mediated immune responses
(Figure 3). On the other hand, in lesional skin of SS, dermal
tumor cells did not express IL-32. It has been recently
Table 1. Results of ELISA, quantitative RT-PCR, and immunohistochemical analysis of IL-32 in CTCL patients
Immunohistochemistry
Age Sex Diagnosis (stage)
Tumor cells in peripheral
blood (countsll–1) ELISA (pgml–1)
Real-time RT-PCR
(ratio to GAPDH) Keratinocytes Tumor cells
50 M Patch MF (IA) 0 ND 0.05 þ 
82 F Patch MF (IA) 0 7.68 1.20 þ þ 
40 M Patch MF (IB) 0 5.21 0.59  
56 F Plaque MF (IB) 0 ND 0.29 þ 
64 M Plaque MF (IB) 0 9.33 0.68 þ þ 
50 F Plaque MF (IA) 0 11.57 1.31 þ þ
40 M Tumor MF (IIB) 0 7.03 1.55 þ þ þ
55 M Tumor MF (IIB) 0 8.77 3.25 þ þ þ
65 F Tumor MF (IIB) 0 10.95 1.00  þ þ
70 M Erythrodermic MF (IIIA) 0 ND 0.30  
64 M Erythrodermic MF (IIIA) 0 8.49 0.11 ND ND
67 M SS (IVA) 30,492 16.73 0.36  
64 F SS (IVA) 2,812 12.19 0.02  þ
42 M SS (IVA) 1,548 12.51 0.04 þ 
Abbreviations: CTCL, cutaneous T-cell lymphoma; F, female; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; M, male; MF, mycosis fungoides; ND, not
done; RT, reverse transcription; SS, Se´zary syndrome.
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proposed that MF and SS are distinct clinical entities,
arising from different T-cell subsets. MF is a malignancy
of skin-resident effector memory T cells and SS originates
from central memory T cells (Campbell et al., 2010). The
apparent lack of IL-32 expression in tumor cells in SS might
support this theory.
IL-32 mRNA expression levels in lesional skin positively
correlated with CCL17 and CCL18 mRNA expression levels
(Figure 1c and d), which were both disease markers of CTCL
(Kakinuma et al., 2003; Gu¨nther et al., 2011; Miyagaki et al.,
2013). In patients with high IL-32 mRNA expression levels in
lesional skin, enhanced IL-32 expression was also detected by
immunohistochemical analysis (Table 1). There was, however,
no significant correlation between serum IL-32 levels and
IL-32 mRNA expression levels in lesional skin. Indeed, there
were no significant differences in serum IL-32 levels between
CTCL patients and healthy controls (Figure 2a). In eight SS
cases, there was no significant correlation between tumor cells
in peripheral blood and serum IL-32 levels (data not shown).
These results suggested that IL-32 expression in lesional skin
may be more important than serum IL-32 in the development
of CTCL, especially in the setting of MF.
In vitro experiments using MF and SS cell lines showed
that IL-32 accelerated CTCL cell proliferation. When we
added cell signaling inhibitors such as U0126, sc-514, and
LY294002 to the culture media, U0126 and sc-514 blocked
the IL-32-mediated proliferation of these cells. These results
suggested that IL-32 induced CTCL cell proliferation through
MAPK and NF-kB pathways. There have been several reports
regarding the downstream signaling pathways of IL-32 (Kim
et al., 2005; Netea et al., 2008; Mabilleau and Sabokbar,
2009; Nakayama et al., 2012). IL-32 induced the production
of tumor necrosis factor-a in mouse macrophage cells through
MAPK and NF-kB pathways (Nakayama et al., 2012). The
IL-32-induced production of tumor necrosis factor-a, IL-1b,
and IL-6 by human peripheral blood mononuclear cells was
similarly regulated through phosphorylation of p38 MAPK
(Netea et al., 2008). On the other hand, others reported that
IL-32 induced massive activation of MAPK and PI3-kinase/Akt
pathways of human peripheral blood mononuclear cell
(Mabilleau and Sabokbar, 2009). Our results were consistent
with the former two papers. Interestingly, aberrant activation
of MAPK and NF-kB pathways has been reported in CTCL
(Izban et al., 2000; Sors et al., 2006; Mao et al., 2008). IL-32
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may be one of the key cytokines activating these signaling
pathways, which are known to contribute toward proliferation
and resistance to apoptosis. IL-32 neutralization significantly
decreased cell numbers of the SS cell line SeAx, while it
significantly decreased the survival rate of the MF cell line
MyLa. This discrepancy may also support the idea that MF and
SS are distinct clinical entities (Campbell et al., 2010).
The role of IL-32 in the setting of other malignancies has
been studied. IL-32 expression was associated with a poorer
prognosis in head and neck squamous cell carcinoma (Guenin
et al., 2013). Expression of IL-32 in human lung cancer
correlated with metastasis (Sorrentino and Di Carlo, 2009).
Other reports, however, reveal a potential anti-proliferative
effect of IL-32. For example, IL-32 silencing in stromal cells
via siRNA abrogated apoptosis in leukemia cells (Marcondes
et al., 2008). IL-32 was also reported to enhance cytotoxic
effects of NK cells, inhibiting tumor cell growth (Cheon
et al., 2011; Oh et al., 2011). Taken together, aberrant
IL-32 expression by tumor cells is associated with tumor
progression, whereas the physiological expression of IL-32
enhances tumor immunity. Our study suggests that IL-32
expression is also dysregulated in advanced MF, but not in
the erythrodermic variant of MF.
In conclusion, this study highlights IL-32 as a cytokine
functioning as an autocrine and paracrine growth factor in
CTCL, especially in MF. Keratinocytes are a main source of this
cytokine in patch and plaque MF, although IL-32 is expressed
by malignant cells in lesional skin of tumor MF and by CTCL
cell lines. Our study suggested that IL-32 may have a role in the
formation and maintenance of CTCL lesions, providing a
possible therapeutic target for patients with this disease.
MATERIALS AND METHODS
Patients and samples
Skin samples were collected from 26 patients with MF/SS (seven cases
of patch MF, eight cases of plaque MF, five cases of tumor MF, and six
cases of erythrodermic MF/SS; seven cases of stage IA, eight cases of
stage IB, four cases of stage IIB, two cases of stage IIIA, three cases of
stage IVA, and two cases of stage IVB) and six healthy control subjects.
Blood samples were collected from 42 patients with MF/SS (25 male
and 17 female patients; SD age: 59.9±13.1 years; 11 cases of patch
MF, 11 cases of plaque MF, 9 cases of tumor MF, and 11 cases of
erythrodermic MF/SS; 12 cases of stage IA, 10 cases of stage IB, 7 cases
of stage IIB, 4 cases of stage IIIA, 7 cases of stage IVA, and 2 cases of
stage IVB) and 20 healthy control subjects (11 male and 9 female
subjects; 42.6±17.3 years). No tumor cells in peripheral blood (B0)
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were detected in any MF patient. The tumor cell load in the peripheral
blood for SS patients ranged from 1,548 to 42,543 countsml–1 (mean:
14,273 countsml–1). All the patients were untreated or treated with only
topical corticosteroid at the time of biopsy or blood test. The diagnosis
of MF/SS was based on the World Health Organization classification
and on the criteria of the International Society for Cutaneous
Lymphomas (Olsen et al., 2007). The healthy controls had no
history of MF/SS or any skin diseases. All samples were collected
after written informed consent was obtained. The medical ethics
committee of the University of Tokyo approved the study, and it was
conducted according to the Declaration of Helsinki Principles.
Quantitative RT-PCR
RNA was obtained from human skin samples with RNeasy Fibrous
Tissue Mini Kit (QIAGEN, Valencia, CA). Complementary DNA was
synthesized using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories,
Berkeley, CA). Quantitative RT-PCR was performed, as described
previously, based on the SYBR Green assay (Sugaya et al., 2012).
Primers for human IL-32 and glyceraldehyde-3-phosphate dehydro-
genase were as follows: IL-32 forward 50-GGAGACAGTGGCGGC
TTAT-30 and reverse 50-GGCACCGTAATCCATCTCTT-30; glycera-
ldehyde-3-phosphate dehydrogenase forward 50-ACCCACTCCTCCA
CCTTTGA-30 and reverse 50-CATACCAGGAAATGAGCTTGACAA-30.
ELISA
Quantification of serum IL-32 levels was performed using the human
IL-32 Quantikine ELISA kit (Biolegend, San Diego, CA), according to
the manufacturer’s instructions.
IL-32 immunohistochemical staining
We also performed immunohistochemical staining for IL-32 using
lesional skin of patch MF (n¼ 5), plaque MF (n¼ 5), tumor MF (n¼ 5),
erythrodermic MF/SS (n¼ 5), and with normal skin (n¼ 5). We used
rabbit anti-human IL-32 polyclonal antibody (Sigma-Aldrich, St Louis,
MO), followed by ABC staining (Vector Lab, Burlingame, CA).
CTCL cell lines
MyLa (an MF cell line) and SeAx (an SS cell line) were kind gifts from
Dr Kazuyasu Fujii (Department of Dermatology, Okayama University,
Okayama, Japan). MyLa and SeAx (4 105) were cultured in 1 ml of
serum-free RPMI1640 (Millipore, Billerica, MA).
IL-32 stimulation and blocking of cell signaling pathways
Recombinant human IL-32a was purchased from BioVision (Milpitas,
CA). To inhibit the cell signaling pathway, U0126 (MAPK extra-
cellular signal–reduced kinase 1/2 inhibitor), sc-514 (IkB kinase-2
inhibitor), and LY294002 (phosphatidylinositol 3-kinase inhibitor)
were purchased from Cell Signaling Technology (Danvers, MA). Cell
counting was performed 48 hours after incubation using the Coulter
Counter. Trypan blue solution was used for cell viability analysis. To
neutralize IL-32 in culture supernatants, we used an anti-IL-32 rabbit
polyclonal antibody purchased from Acris Antibody (San Diego, CA).
Isotype-matched antibody was used as a control.
Statistical analysis
Statistical analysis was performed using the Mann–Whitney U-test
and Student’s t-test for the comparison of values. P-values o0.05
were considered statistically significant.
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